Zacks Investment Research cut shares of Eagle Pharmaceuticals (NASDAQ:EGRX) from a strong-buy rating to a hold rating in a research note released on Tuesday morning.

According to Zacks, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. “

A number of other equities research analysts have also recently commented on EGRX. ValuEngine upgraded shares of Eagle Pharmaceuticals from a hold rating to a buy rating in a report on Monday, October 2nd. Piper Jaffray Companies restated a buy rating and issued a $75.00 price target on shares of Eagle Pharmaceuticals in a report on Friday, October 27th. Mizuho restated a sell rating and issued a $37.00 price target on shares of Eagle Pharmaceuticals in a report on Wednesday, November 8th. Royal Bank of Canada restated an outperform rating and issued a $75.00 price target (down from $81.00) on shares of Eagle Pharmaceuticals in a report on Thursday, November 9th. Finally, BidaskClub upgraded shares of Eagle Pharmaceuticals from a hold rating to a buy rating in a report on Saturday, December 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. Eagle Pharmaceuticals currently has an average rating of Hold and a consensus target price of $62.33.

Eagle Pharmaceuticals (EGRX) traded down $0.47 during trading hours on Tuesday, reaching $62.09. 319,808 shares of the company’s stock were exchanged, compared to its average volume of 209,402. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.30 and a quick ratio of 5.15. The firm has a market capitalization of $933.50, a PE ratio of 9.87 and a beta of 1.24. Eagle Pharmaceuticals has a 1-year low of $45.05 and a 1-year high of $97.15.

Several institutional investors have recently added to or reduced their stakes in EGRX. Schwab Charles Investment Management Inc. lifted its stake in shares of Eagle Pharmaceuticals by 2.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 37,053 shares of the specialty pharmaceutical company’s stock valued at $2,924,000 after buying an additional 737 shares in the last quarter. First Trust Advisors LP bought a new position in shares of Eagle Pharmaceuticals in the second quarter valued at $1,989,000. State of Wisconsin Investment Board bought a new position in shares of Eagle Pharmaceuticals in the second quarter valued at $473,000. Bank of New York Mellon Corp lifted its stake in shares of Eagle Pharmaceuticals by 0.4% in the second quarter. Bank of New York Mellon Corp now owns 116,510 shares of the specialty pharmaceutical company’s stock valued at $9,191,000 after buying an additional 482 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in shares of Eagle Pharmaceuticals by 3.9% in the second quarter. Legal & General Group Plc now owns 14,984 shares of the specialty pharmaceutical company’s stock valued at $1,182,000 after buying an additional 563 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: This piece was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2018/01/13/zacks-investment-research-downgrades-eagle-pharmaceuticals-egrx-to-hold.html.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.